PUBLISHER: DelveInsight | PRODUCT CODE: 1246747
PUBLISHER: DelveInsight | PRODUCT CODE: 1246747
"Sonelokimab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Sonelokimab for Hidradenitis Suppurativa (HS) in the 7MM. A detailed picture of the Sonelokimab for Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Sonelokimab for Hidradenitis Suppurativa. The report provides insight about mechanism of action, dosage, and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Sonelokimab market forecast, analysis for Hidradenitis Suppurativa in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hidradenitis Suppurativa.
Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema. The drug is currently in the Phase II stage of development for treating the patients with hidradenitis suppurativa (HS).
Sonelokimab has the potential to elevate patient outcomes due to its ability to inhibit the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation in many inflammatory diseases, and its Nanobody characteristics should additionally improve tissue penetration, helping the molecule to target difficult-to-reach inflammatory lesions. Top-line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody sonelokimab, expected mid-2023.
In February 2023, MoonLake Immunotherapeutic announced that it had completed enrollment of the target 210 patients randomized ahead of schedule in its global Phase II clinical trial evaluating sonelokimab in moderate-to-severe hidradenitis suppurativa (HS).
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.
This report provides a detailed market assessment of Sonelokimab in Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of Sonelokimab in Hidradenitis Suppurativa covering trial interventions, trial conditions, trial status, start and completion dates.